Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication Neurogastrx Announces Positive POC Data for Investigational Drug NG101 in Reducing Nausea & Vomiting Associated with GLP-1 Agonists

Opioid-Induced Constipation Market Trends, Epidemiology, and Unmet Needs to 2034: 7MM Projected to Reach $1.16 Billion Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Opioid-Induced Constipation Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ...

Viral Gastroenteritis Global Market Report 2023: A $7.68 Billion Market by 2027 - Product Innovation and FDA Approvals Fuel Growth to 2032 Dublin, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The "Viral Gastroenteritis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global viral gastroenteritis market is...

Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer CAMPBELL, Calif., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Neurogastrx, a biopharmaceutical company engaged in developing novel drugs for gastrointestinal disorders, today announced the appointment of...